Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peficitinib Phase 2b Dose-Response Study in Ulcerative Colitis
NCT01959282Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2013
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of peficitinib in ulcerative colitis (UC) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change from baseline in the Mayo score at 8 weeks. Started Nov 2013; status: completed.
02
Drugs
peficitinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01959282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01959282.